이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

자간전증의 산모-태아 인터페이스에 대한 분자 연구. (PREMAFE)

2026년 11월 3일 업데이트: Carlos Simon Foundation

단일 세포 기술을 이용한 자간전증 발병에 대한 모체-태아 인터페이스의 분자적 연구.

Preeclampsia (PE) is a major obstetric complication with short- and long-term consequences for the mother and the fetus. Early screening tools to reduce its mortality and morbidity, as well as to prevent the life-threatening consequences are needed. Thus, the detection of women at risk of suffering PE is key to apply preventive and treatment strategies. Recently, the maternal contribution to PE based on defective decidualization that prevents the establishment of a functional maternal-fetal interface has been evidenced. The main objective of this study is to identify molecular markers or aberrant maternal-fetal cell types that can be detected early in the development of the disease in maternal-fetal interface tissue (chorionic villi + decidua) collected during gestational weeks 9 to 15. Maternal-fetal interface biopsy will be collected from women who have a recommendation for aneuploidy testing. The remaining fragment will be used for this study.

연구 개요

상세 설명

The hypothesis is that those women who develop PE have impaired decidualization associated with shallow cytotrophoblast invasion during the development of the maternal-fetal interface whose molecular profile analysis at the single cell level will allow characterization of PE development prior to the onset of symptoms.

The purposed study is a biomedical, prospective, multicentre, case-control aimed to characterize the molecular profile of the maternal-fetal interface in the first trimester of pregnancy early in the development of preeclampsia using single-cell sequencing technology. Distinguishing the maternal and fetal origin of the chorionic biopsy cells, describing the maternal-fetal interface and deciphering the intercellular communications and altered pathways in PE and other obstetric complications could be suggested as a secondary outcome, as well as the characterization of the blood sample, the epigenome and metabolome of single cells or the validation of markers of the different cell types. Another objective will be to perform a molecular characterization of maternal-fetal blood and tissue samples collected at the time of delivery, with the aim of correlating the alterations detected in the first trimester with the molecular profiles at the end of pregnancy in both PE patients and controls.

Subjects will be 2084 pregnant women over the age of 18 recruited between 9 and 15 gestational weeks. Patients attending the participating referral centers for a chorionic villus biopsy due to the detection of a foetal chromosomal abnormality risk will provide the leftover chorionic biopsy sample after determination of the risk of trisomies and a peripheral blood sample for genotyping of maternal lymphocytes and circulating cRNA.

Data will be registered in an electronic Case Report Form (eCRF) specifically designed for this study. Monitoring activities and data verification will be performed during the whole study to ensure data quality, integrity and transparency.

The total estimated duration of the study is 52 months, of which the first 48 months will correspond to the recruitment period of the participants.

연구 유형

관찰

등록 (추정된)

2084

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Carlos Simón, MD, PhD

연구 연락처 백업

연구 장소

    • Alicante
      • Alicante, Alicante, 스페인
        • 모병
        • Hospital General Universitario Dr. Balmis
        • 연락하다:
    • Murcia
      • Murcia, Murcia, 스페인
        • 모병
        • Hospital Clinico Universitario Virgen de la Arrixaca
        • 연락하다:
    • Santa Cruz de Tenerife
      • Santa Cruz de Tenerife, Santa Cruz de Tenerife, 스페인
        • 모병
        • Hospital Universitario de Canarias
        • 연락하다:
        • 부수사관:
          • Walter Plasencia Acevedo
    • Valencia
      • Valencia, Valencia, 스페인
        • 모병
        • Hospital Universitario y Politécnico La Fe
        • 연락하다:
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

해당 없음

연구 대상 성별

여성

샘플링 방법

비확률 샘플

연구 인구

The study population will consist of women aged 18 years or older with singleton pregnancies who, depending on their stage of pregnancy and willingness to participate, may be enrolled in one or both phases of the study:

  • Phase 1 (first trimester): Women attending the participating referral centers between 9 and 15 weeks of gestation to undergo chorionic villus sampling (CVS), either due to an increased risk of fetal chromosomal abnormalities identified through non-invasive prenatal screening or for any other medical indication. In these cases, participants will be asked to donate surplus chorionic villus tissue obtained during the diagnostic procedure, as well as a peripheral blood sample.
  • Phase 2 (delivery): Women who, regardless of whether they participated in the initial phase of the study, agree to donate placental tissue and maternal blood samples at the time of delivery. Participation in this phase may be offered at later stages of pregnancy.

설명

Inclusion Criteria:

  • Patients whose written informed consent approved by the Ethics Committee (EC) has been obtained, after having been duly informed of the nature of the study and voluntarily accepted to participate after being fully aware of the potential risks, benefits and any discomfort involved.
  • Women over the age of 18 at the time of signing the informed consent form.
  • Women who meet at least one of the following criteria at the time of inclusion:

Phase 1 (first trimester): Pregnant women between 9 and 15 weeks of gestation who are scheduled to undergo chorionic villus sampling (CVS) as part of the center's routine clinical practice.

Phase 2 (delivery): Women with an ongoing pregnancy, regardless of gestational age and without the requirement of having participated in Phase 1, who are willing to donate placental and maternal blood samples following delivery.

Exclusion Criteria:

  • Women with multiple pregnancy.
  • Non-evolving pregnancies (including delayed abortion/foetal orbit).

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: CASE_CONTROL
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
개입 / 치료
Cases group (phase 1)

Women recruited between 9 and 15 gestational weeks diagnosed with preeclampsia or other complication at the end of pregnancy.

Maternal-fetal interface tissue (chorionic villi and decidua) will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in cases group. Clinical data will be compiled.

Maternal-fetal interface tissue (placenta) and peripheral blood will be collected from women who develop preeclampsia or other obstetric complication at the end of their pregnancy. Clinical data will be compiled.

Control group (phase 1)

Women recruited between 9 and 15 gestational weeks without diagnosis of preeclampsia or other complication at the end of the pregnancy

Maternal-fetal interface tissue (chorionic villi and decidua) will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in control group. Clinical data will be compiled.

Maternal-fetal interface tissue (placenta) and peripheral blood will be collected from women who do not experience any complications or who do not experience the specific obstetric complication defined in the case group to which they are compared.

Cases group (phase 2)

Women recruited at delivery with preeclampsia or other complication.

Maternal-fetal interface tissue (chorionic villi and decidua) will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in cases group. Clinical data will be compiled.

Maternal-fetal interface tissue (placenta) and peripheral blood will be collected from women who develop preeclampsia or other obstetric complication at the end of their pregnancy. Clinical data will be compiled.

Control group (phase 2)

Women recruited at delivery with no obstetric complication or who do not experience the specific obstetric complication defined in the case group to which they are compared.

Maternal-fetal interface tissue (chorionic villi and decidua) will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in control group. Clinical data will be compiled.

Maternal-fetal interface tissue (placenta) and peripheral blood will be collected from women who do not experience any complications or who do not experience the specific obstetric complication defined in the case group to which they are compared.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
To charactize the molecular profile of the maternal-fetal interface (chorionic billi and decidua) between 9 and 15 weeks of gestation in healthy and preeclamptic pregnancies
기간: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks

Differentially expressed genes between control vs preeclampsia group at the level of cell types/subtypes

From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
To characterise the molecular profile of the maternal-fetal interface between 9 and 15 weeks of gestation in pregnancies diagnosed with pregnancy complication other than preeclampsia
기간: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks

Differentially expressed genes between control vs cases group at the level of cell types/subtypes.

From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks
To characterise the epigenome and metabolome of individual cells from the maternal-fetal interface in healthy pregnancies and those diagnosed with preeclampsia or other pregnancy complication
기간: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks

Differentially methylation profiles and differentially metabolites between control vs cases group at the level of cell types/subtypes.

From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks
The discovery and validation of molecular markers as candidates for early diagnosis and/or therapy
기간: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks

Area Under the ROC Curve and/or cell type phenotyping in in vitro cultures after disrupting the candidate

From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks
To characterize the molecular profile of the maternal-fetal interface (placenta) at the end of pregnancy in healthy and preeclamptic pregnancies
기간: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks

Differentially expressed genes between control vs preeclampsia group at the level of cell types/subtypes

From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Tamara Garrido, PhD, Fundación Carlos Simon para la investigación en salud de la mujer

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 11월 20일

기본 완료 (추정된)

2027년 12월 1일

연구 완료 (추정된)

2027년 12월 1일

연구 등록 날짜

최초 제출

2024년 1월 22일

QC 기준을 충족하는 최초 제출

2024년 1월 22일

처음 게시됨 (실제)

2024년 1월 31일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 3일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다